Selective COX-2 Inhibitors
Pharmacology, Clinical Effects and Therapeutic Potential
Published on 31. January 1998
Book
Hardback
160 pages
978-0-7923-8729-9 (ISBN)
Description
This volume is the proceedings of the William Harvey Research Conference held in Cannes, France, on the 20th and 21st March, 1997. It describes the present knowledge of the structures of the cyclooxygenase isoforms and the experimental and clinical effects of selective inhibitors of cyclooxygenase-2. The pathophysiological significance of the cyclooxygenase enzymes in tumorigenesis, programmed cell death, vascular disease and asthma is also covered.
More details
Language
English
Place of publication
United States
Target group
College/higher education
Professional and scholarly
Product notice
sewn/stitched
Cloth over boards
Illustrations
index
Dimensions
Height: 241 mm
Width: 160 mm
Thickness: 15 mm
Weight
418 gr
ISBN-13
978-0-7923-8729-9 (9780792387299)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Sir John R. Vane | Jack H. Botting
Selective COX-2 Inhibitors
Pharmacology, Clinical Effects and Therapeutic Potential
E-Book
12/2012
Springer
€96.29
Available for download
Sir John R. Vane | Jack H. Botting
Selective COX-2 Inhibitors
Pharmacology, Clinical Effects and Therapeutic Potential
Book
11/2012
Springer
€106.99
Shipment within 15-20 days
Persons
Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK.
Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids. Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK.
Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids. Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK.
Content
Preface. 1. Mechanism of Action of Anti-Inflammatory Drugs: An Overview; J.R. Vane, R.M. Botting. 2. The Structure of Human COX-2 and Selective Inhibitors; M.F. Browner. 3. Differential Inhibition of COX-1 and COX-2 by NSAIDs: A Summary of Results Obtained Using Various Test Systems; M. Pairet, et al. 4. COX-2 in Brain and Retina: Role in Neuronal Survival; N.G. Bazan, et al. 5. COX-2 and Apoptosis: NSAIDs as Effectors of Programmed Cell Death; D.L. Simmons, et al. 6. Inhibition of Intestinal Tumorigenesis via Selective Inhibition of COX-2; R.N. DuBois, et al. 7. Cyclooxygenase Enzymes in Human Vascular Disease; C. Patrono, et al. 8. Gastrointestinal Effects of NSAIDs; C.J. Hawkey. 9. Renal Side-Effects of NSAIDs: Role of COX-1 and COX-2; J.C. Frolich, D.O. Stichtenoth. 10. Aspirin-Induced Asthma and Cyclooxygenases; R.J. Gryglewski. 11. New Classification of Aspirin-like Drugs; H. Fenner. 12. New Highly Selective COX-2 Inhibitors; A.W. Ford-Hutchinson. 13. Specific COX-2 Inhibitors: From Bench to Bedside; P. Isakson, et al. 14. Meloxicam: Selective COX-2 Inhibition in Clinical Practice; D.E. Furst.